Endoscopic Vessel Harvesting Devices Market | Latest Statistics, Business Trends, Growth and Opportunities

Market Summary and Growth Forecast

The global Endoscopic Vessel Harvesting Devices Market is estimated at $560 million in 2026 and is expected to reach $875 million by 2035, growing at a CAGR of 5.1%.

Endoscopic vessel harvesting devices are used to remove blood vessels through small incisions, mainly the saphenous vein from the leg and the radial artery from the arm. These vessels are then used as bypass grafts in coronary artery bypass grafting, or CABG. The business relevance is clear. CABG remains a critical option for patients with complex coronary artery disease, especially when multi-vessel disease, diabetes, or left main coronary involvement makes stenting less suitable.

The market is not a broad endoscopy story. It is a focused cardiac surgery device category. Revenue comes from disposable harvesting kits, reusable scopes, access systems, energy-based cutting and coagulation components, and related procedural accessories. In practice, the value pool is heavily linked to CABG procedure volume, surgeon preference, hospital procurement contracts, and training depth inside cardiac surgery teams.

Cardiovascular disease continues to provide the clinical base for demand. WHO identifies cardiovascular diseases as the leading cause of death globally, with coronary heart disease forming a major part of the burden. That keeps surgical revascularization relevant even as percutaneous coronary intervention expands in many countries. In the United States alone, recent clinical literature notes more than 200,000 CABG procedures annually, including around 160,000 isolated CABG cases, which gives the device category a stable anchor in high-value cardiac surgery.

For the Endoscopic Vessel Harvesting Devices Market, growth from 2026 to 2035 will come from three places. First, more hospitals in Asia Pacific, Latin America, and parts of the Middle East are upgrading cardiac surgery programs. Second, surgeons and hospitals are trying to reduce wound complications, recovery time, and visible scarring after vessel harvesting. Third, device suppliers are improving ergonomics, visualization, cutting control, and procedural consistency.

The regulatory environment is also becoming more important. In 2024, Getinge received U.S. FDA 510(k) clearance for its newer Vasoview Hemopro 3 platform. At the same time, FDA recall and shortage notices around earlier EVH systems showed how sensitive this market is to supply continuity, product quality, and safety documentation. This may push hospitals to diversify approved suppliers instead of relying too heavily on a single platform.

Key consumers and clients include cardiac surgery departments, tertiary hospitals, specialty heart centers, integrated delivery networks, group purchasing organizations, public hospital procurement agencies, and private hospital chains. Device manufacturers also sell into teaching hospitals because trained harvesters and surgeons influence platform loyalty over time.

North America remains the most commercially mature market. Europe is more mixed, with strong uptake in advanced cardiac centers but uneven use across countries. Asia Pacific is the most strategic growth region, especially where cardiac surgery infrastructure is expanding. LAMEA will remain smaller but selective private hospitals and national cardiac programs can create steady pockets of demand.

Expert view: The market’s growth will not come from a sudden jump in CABG volume. It will come from a higher share of bypass procedures using endoscopic harvesting rather than open harvesting. That shift is slower, but it is more dependable.

Market Segmentation and Forecast Scope

The Endoscopic Vessel Harvesting Devices Market is best segmented by Product Type, Vessel Type, Application, End User, and Region. This structure reflects how the product is actually bought and used. Hospitals do not purchase EVH devices as generic endoscopy tools. They assess them based on conduit quality, incision size, procedural time, staff training, energy safety, disposables cost, and supplier reliability.

By Product Type

The market includes Disposable EVH Systems, Reusable Endoscopes and Visualization Components, Access and Sealing Accessories, and Service, Training, and Support Components.

Disposable EVH Systems form the commercial center of the category. These include single-use dissectors, harvesters, cannulas, trocars, and energy-enabled components used during the harvesting procedure. This segment is estimated to account for 68% of global revenue in 2026. The high share is logical because most procedures require a sterile disposable kit, while reusable scopes and towers have longer replacement cycles.

Reusable Endoscopes and Visualization Components are lower in recurring revenue but important in platform selection. A hospital may stay with a supplier because the visualization workflow, scope compatibility, and staff familiarity are already in place.

Access and Sealing Accessories are smaller but important. These products influence bleeding control, branch management, and tissue handling. Even small design improvements can affect surgeon confidence.

Service, Training, and Support Components will become more important through 2035. The device has a learning curve. Hospitals that want predictable outcomes need structured training for physician assistants, surgical technologists, and harvesting specialists.

By Vessel Type

The major vessel categories are Saphenous Vein Harvesting and Radial Artery Harvesting.

Saphenous Vein Harvesting remains the leading use case because the great saphenous vein is still commonly used in CABG. It has a deep procedural base and a larger installed user base.

Radial Artery Harvesting is the more strategic growth area. It is gaining attention as surgeons increasingly consider multi-arterial grafting in selected patients. The segment is still smaller, but it carries higher innovation value because radial artery harvesting requires careful handling, better visualization, and strong training discipline.

By Application

The application scope includes Coronary Artery Bypass Grafting, Peripheral Artery Bypass, and Other Arterial Bypass Procedures.

Coronary Artery Bypass Grafting is the dominant application and is expected to remain so throughout 2026–2035. EVH devices are mainly designed around CABG workflows. Terumo’s VirtuoSaph Plus system, for example, is positioned for saphenous vein and radial artery harvesting for CABG and peripheral bypass procedures.

Peripheral Artery Bypass represents a smaller opportunity. It is relevant where vascular surgeons need autologous conduits and want to reduce wound complications. Adoption depends on procedure volume and surgeon training, so growth will be selective rather than broad-based.

By End User

The main end users are Hospitals, Specialty Cardiac Centers, Academic and Teaching Hospitals, and Ambulatory Surgical Settings.

Hospitals are estimated to hold 82% of global demand in 2026 because CABG is an operating-room-intensive procedure requiring cardiac anesthesia, perfusion support, ICU backup, and post-operative monitoring. Standalone outpatient settings do not play a major role.

Specialty Cardiac Centers are highly important commercially. They may not always represent the largest count of facilities, but they often influence training standards, brand perception, and surgeon preference.

Academic and Teaching Hospitals matter because EVH technique adoption depends on skill transfer. A device that is easier to teach can gain share even if its unit price is not the lowest.

By Region

The regional scope covers North America, Europe, Asia Pacific, and LAMEA.

North America leads on value because of higher EVH penetration, stronger reimbursement coverage, premium device pricing, and established cardiac surgery programs. FDA-cleared devices and hospital contracting structures shape the competitive field.

Europe remains steady but fragmented. Germany, the United Kingdom, France, Italy, the Netherlands, and Nordic countries show stronger procedure infrastructure. Adoption varies because clinical practice patterns and procurement systems differ across countries.

Asia Pacific is the fastest-growing region. China, India, Japan, South Korea, and Southeast Asian cardiac centers are expanding access to advanced cardiac surgery. The region’s growth will not be uniform. Japan and South Korea are mature and quality-led. India and China offer larger procedure-volume expansion but stronger price pressure.

LAMEA is smaller but not insignificant. Brazil, Mexico, Saudi Arabia, the UAE, and South Africa are the most relevant markets. Private hospital groups and national cardiac care investments will support selective adoption.

Expert view: The best growth signal is not just how many CABG procedures a country performs. It is whether hospitals have trained harvesters, stable disposable supply, and reimbursement that recognizes minimally invasive harvesting as part of quality cardiac care.

Market Trends and Innovation Landscape

Innovation in the Endoscopic Vessel Harvesting Devices Market is practical rather than flashy. Hospitals are not asking for complex digital platforms first. They want devices that reduce conduit trauma, improve visibility, shorten the learning curve, and avoid avoidable intraoperative interruptions. That makes engineering reliability a commercial differentiator.

The first trend is better procedural control. Newer EVH systems are being designed around improved ergonomics, easier tissue dissection, more controlled branch sealing, and better visibility inside the tunnel. This matters because small movements can affect the vessel wall. A harvesting device has to balance speed with graft protection. Faster is useful. But a clean conduit is the real objective.

The second trend is platform refinement after safety scrutiny. FDA actions in 2024 and 2025 around earlier VasoView HemoPro models raised attention on silicone detachment risk, product recalls, and EVH device supply concerns. These events do not weaken the long-term market need. They sharpen procurement behavior. Hospitals may now ask harder questions on lot traceability, failure reporting, replacement availability, and supplier contingency planning.

The third trend is broader validation of device alternatives. Getinge, Terumo, and Saphena Medical / Zimmer Biomet are all relevant in the competitive ecosystem. Terumo’s VirtuoSaph Plus has CE and FDA approval for endoscopic vein and radial artery harvesting, according to product information from Terumo Europe. Saphena Medical’s Venapax is positioned as a unitary system that combines dissection and branch ligation, with a design focus on minimal-touch harvesting.

The fourth trend is training-led adoption. EVH is not just a device purchase. It is a procedural skill. A hospital with a strong cardiac surgery program may still hesitate if it lacks experienced harvesters. That is why learning platforms, clinical support, and proctoring programs can affect sales conversion. Terumo promotes EVH learning resources around its platform, which reflects how suppliers are moving beyond product-only selling.

The fifth trend is radial artery readiness. As selected CABG patients receive more arterial grafting strategies, device makers will need systems that work well for both leg and arm harvesting. The design challenge is different. The radial artery is smaller and more sensitive to handling. Devices that support clean visualization, controlled dissection, and consistent branch management will have a stronger technical story.

AI integration is not yet a major commercial force in this market. It may appear later in training simulation, video analytics, surgeon education, or procedural benchmarking. But it is not currently a core purchase driver for EVH systems. So, the near-term innovation focus remains mechanical design, visibility, energy control, safety, and training.

Mergers and partnerships have been limited but meaningful. The KARL STORZ and Saphena Medical partnership to provide integrated EVH solutions is a good example of how visualization companies and harvesting device firms can combine strengths. It also shows that the market still has room for system-level collaboration rather than only standalone device competition.

Recent announcements also point to product refresh cycles. Getinge’s 2024 FDA clearance for Vasoview Hemopro 3 shows that established players are still investing in platform upgrades. FDA’s later safety and shortage communications show the other side of the same market: innovation must be matched with quality assurance and supply resilience.

Expert view: By 2035, the Endoscopic Vessel Harvesting Devices Market should look more consolidated around platforms that combine reliable disposables, strong training, and documented safety performance. Hospitals will not simply buy the lowest-cost kit. They will buy the system that protects procedure flow and reduces clinical uncertainty.

Competitive Intelligence and Benchmarking

The competitive structure of the Endoscopic Vessel Harvesting Devices Market is narrow but technically demanding. This is not a crowded commodity device category. The supplier base is built around companies that can combine device reliability, energy control, endoscopic access, clinical training, regulatory clearance, and hospital contracting.

In 2026, the top 5–7 players control most global value. That said, market share does not come only from product availability. It comes from surgeon comfort, harvester training, recall history, replacement supply, and whether the device can support both saphenous vein and radial artery workflows.

Getinge remains the reference player. Its cardiovascular surgery franchise has strong recognition and its EVH systems are designed for conduit harvesting from the saphenous vein and radial artery. The company’s newer platform was cleared by the U.S. FDA in March 2024, with design changes around smoke evacuation, energy control, ergonomics, and cable integration. That gives Getinge product refresh strength. But the company also faces higher scrutiny after FDA safety and shortage communications around earlier systems.

Terumo Cardiovascular is the most credible second pole in the category. Its EVH system has CE and FDA approval for both endoscopic vein and radial artery harvesting. The company also supports training through EVH and ERAH learning platforms. This matters because hospitals do not adopt EVH purely through procurement. They adopt it when the harvester team can perform the technique safely and repeatedly.

Zimmer Biomet / Saphena Medical is important because it brings a different design logic. Saphena Medical’s system uses a unitary structure that combines dissection and branch ligation. The company positions the platform around minimal-touch harvesting and a shorter learning curve. This is commercially relevant in hospitals that struggle with EVH training depth or want to reduce procedural variability.

KARL STORZ plays a more indirect but useful role. The company’s strength is endoscopic imaging and visualization. Its partnership with Saphena Medical showed how EVH may evolve through bundled solutions rather than only single-device sales. For hospitals, the logic is simple. A harvesting device is easier to adopt when visualization, access, and procedural support are integrated.

Med Europe S.r.l. is a smaller but relevant competitor. Its EVH system is indicated for video-assisted vessel harvesting and is positioned for the saphenous vein, radial artery, and in situ peripheral bypass use. It does not have the same global scale as Getinge or Terumo. Still, it can compete in selected tenders where buyers want alternatives and acceptable procedural functionality.

LivaNova / Sorin’s legacy EVH portfolio remains part of the installed-base discussion. The platform includes optical dissection, retraction, bipolar cutting, and vein scissors. Its current market role is more selective. It is not the main innovation reference, but it can remain relevant where hospitals have older capital systems, trained users, or local distributor support.

Expert view: Competitive advantage in this category is not only device design. It is the ability to keep trained users confident. One recall, one shortage, or one repeated intraoperative failure can shift procurement behavior faster than a minor price discount.

Regional Landscape and Adoption Outlook

Regional adoption in the Endoscopic Vessel Harvesting Devices Market follows cardiac surgery infrastructure. Countries with high CABG capacity, trained harvesting teams, and stable hospital funding use EVH more consistently. Countries with lower cardiac surgery access or strict price pressure use EVH more selectively.

The global revenue pool is estimated at $560 million in 2026. North America holds the highest value share because of premium pricing and deeper procedural penetration. Asia Pacific is smaller in value but stronger in growth. Europe sits between the two, with strong clinical capability but tighter reimbursement and procurement pressure.

United States

The United States is the largest single-country market. Its 2026 EVH device revenue is estimated at $215 million, or about 38% of global demand. The country has high CABG procedure depth, strong hospital purchasing capacity, and a large base of trained physician assistants and surgical technologists who perform vessel harvesting in cardiac surgery teams.

The U.S. market is also more sensitive to FDA actions than any other region. FDA communications in 2024 and 2025 around EVH device recalls and shortages pushed hospitals to review alternative suppliers, inspect devices more closely, and strengthen product traceability. This does not reduce the value of EVH. It makes supplier reliability more important.

Europe

Europe is estimated at $140 million in 2026 and may reach $205 million by 2035. Germany, the United Kingdom, France, Italy, the Netherlands, and Nordic countries are the most relevant demand centers. Adoption is strongest in high-volume cardiac surgery hospitals and teaching centers.

Regulation is a major market filter. The EU Medical Device Regulation has increased the importance of clinical evidence, post-market surveillance, and compliance documentation. The European Commission also proposed targeted simplification of medical device rules in December 2025, which may improve administrative efficiency while preserving safety oversight. For EVH suppliers, this means regulatory quality is no longer back-office work. It is part of market access.

China

China is the most important long-term growth market after the U.S. and Europe. The market is estimated at $55 million in 2026 and may more than double to $115 million by 2035. China’s disease burden supports the demand base. A recent cardiovascular health report estimated 330 million people in China with cardiovascular disease and 11.39 million with coronary heart disease.

The adoption gap is not clinical need. It is hospital segmentation. Tier-1 urban hospitals can adopt premium EVH systems. Lower-tier hospitals may remain slower because of cost, training, and procurement approvals. So, growth will concentrate first in top cardiac centers in Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, and other large medical hubs.

India

India is estimated at $30 million in 2026, rising to $75 million by 2035. The country has a large coronary disease burden and strong private cardiac surgery chains. The adoption challenge is pricing. Many hospitals still evaluate disposable EVH kits against open harvesting cost. That limits penetration outside premium hospitals.

Public financing may improve access over time. Ayushman Bharat PM-JAY provides health coverage of up to ₹5 lakh per entitled family for secondary and tertiary hospitalisation, and the scheme targets more than 12 crore families. It also covers public and private empanelled hospitals. This type of financing can support cardiac procedure volumes, although EVH adoption will still depend on package economics and hospital margin.

Japan

Japan is mature and quality-driven. The country has sophisticated cardiovascular surgery infrastructure and strong outcome documentation through national clinical databases. Growth is expected to be modest because procedure volumes are not expanding rapidly. The opportunity is replacement demand, radial artery harvesting support, and premium platform upgrades.

Japan’s value pool is estimated at $38 million in 2026, reaching $52 million by 2035. Adoption will stay concentrated in advanced cardiac centers and university hospitals. Procurement will prioritize clinical reliability, staff familiarity, and device traceability.

South Korea

South Korea is smaller but attractive. Its 2026 revenue is estimated at $18 million, reaching $30 million by 2035. The country has advanced hospital infrastructure, high device-quality expectations, and strong teaching hospitals. Growth will come from premium cardiac centers rather than broad hospital expansion.

South Korea is also an important reference market for Asia Pacific adoption. A supplier that performs well in Seoul’s top hospitals can use that credibility in other Asian markets.

Middle East

The Middle East is relevant where cardiac centers are being upgraded. Saudi Arabia, the UAE, Qatar, and Kuwait are the most important markets. The regional value pool is estimated at $22 million in 2026, growing to $45 million by 2035.

Demand is driven by tertiary hospital investment, private specialty centers, medical tourism, and high cardiovascular risk in the population. Adoption will remain concentrated. Large government hospitals and premium private facilities will buy EVH systems. Smaller hospitals may not have enough CABG volume to justify frequent disposable use.

Expert view: The next phase of regional growth will be uneven. The United States will buy on safety and continuity. Europe will buy on compliance and evidence. Asia will buy on training, affordability, and cardiac surgery capacity. This split matters for every supplier’s commercial playbook.

Recent Developments + Opportunities & Restraints

Recent Developments

Opportunities

1. Emerging-market cardiac surgery expansion

China, India, Southeast Asia, and GCC countries offer the strongest white space. The opportunity is not just more CABG cases. It is the conversion of open harvesting to EVH in larger cardiac centers. If even 10–15% of eligible bypass procedures in large emerging-market hospitals shift to EVH over the next decade, the incremental disposable revenue pool becomes meaningful.

2. Training as a commercial product

EVH adoption has a real learning curve. Suppliers that package device sales with structured training, simulation, proctoring, and outcome review can improve conversion. This is especially useful in India, China, the Middle East, and Latin America. In this market, training is not a support function. It is a revenue enabler.

3. Dual-vessel capability

Radial artery harvesting is a strategic opportunity. Hospitals using more arterial grafting strategies will prefer systems that can support both saphenous vein and radial artery workflows. This may allow premium pricing in advanced cardiac centers.

Business Restraints

1. Product recalls and safety perception

Recent FDA recall activity shows that EVH systems carry reputational risk. A device failure can delay surgery, force conversion to open harvesting, or create retained-fragment concerns. This makes safety history a commercial differentiator.

2. Disposable cost pressure

Many hospitals in price-sensitive markets compare EVH kits with the lower direct cost of open harvesting. EVH may reduce wound morbidity and recovery burden, but the savings are not always captured in device budgets. That creates adoption friction.

3. Limited trained harvesters

A hospital can buy the device but still fail to use it consistently. Low procedural confidence leads to underutilization. This is a major barrier in mid-tier hospitals and emerging markets.

Expert view: The best commercial opportunity is not selling more boxes. It is building repeatable EVH programs inside hospitals. A trained team, reliable supply, and clear complication-reduction story can convert EVH from a premium option into a standard CABG workflow.